| MeSH term | MeSH ID | Detail |
|---|---|---|
| Bronchiolitis | D001988 | 6 associated lipids |
| Bronchiolitis Obliterans | D001989 | 8 associated lipids |
| Bronchitis | D001991 | 6 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Chlamydia Infections | D002690 | 7 associated lipids |
| Chromoblastomycosis | D002862 | 2 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Confusion | D003221 | 4 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Morikawa K et al. | Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. | 1996 | Antimicrob. Agents Chemother. | pmid:8726002 |
| Arain TM et al. | Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. | 1996 | Antimicrob. Agents Chemother. | pmid:8726034 |
| Svensson M et al. | Pharmacodynamic effects of nitroimidazoles alone and in combination with clarithromycin on Helicobacter pylori. | 2002 | Antimicrob. Agents Chemother. | pmid:12069981 |
| Gibreel A et al. | Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. | 2007 | Antimicrob. Agents Chemother. | pmid:17606685 |
| Maurin M and Raoult D | In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8109928 |
| O'Hara K and Yamamoto K | Reaction of roxithromycin and clarithromycin with macrolide-inactivating enzymes from highly erythromycin-resistant Escherichia coli. | 1996 | Antimicrob. Agents Chemother. | pmid:8849224 |
| Endo H et al. | Effects of lansoprazole and amoxicillin on uptake of [(14)C]clarithromycin into gastric tissue in rats. | 2001 | Antimicrob. Agents Chemother. | pmid:11709323 |
| la Porte CJ et al. | Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. | 2009 | Antimicrob. Agents Chemother. | pmid:19015362 |
| Goswami S et al. | Anti-Helicobacter pylori potential of artemisinin and its derivatives. | 2012 | Antimicrob. Agents Chemother. | pmid:22687518 |
| Giacometti A et al. | In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. | 2007 | Antimicrob. Agents Chemother. | pmid:17220421 |
| Vermot D et al. | Efficacy of clarithromycin versus that of clindamycin for single-dose prophylaxis of experimental streptococcal endocarditis. | 1996 | Antimicrob. Agents Chemother. | pmid:8851620 |
| Alder J et al. | Clarithromycin therapy of experimental Treponema pallidum infections in hamsters. | 1993 | Antimicrob. Agents Chemother. | pmid:8494384 |
| Dega H et al. | Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. | 2002 | Antimicrob. Agents Chemother. | pmid:12234844 |
| Endo H et al. | Effects of clarithromycin and amoxicillin on gastric emptying in rats. | 2002 | Antimicrob. Agents Chemother. | pmid:12234874 |
| Yasuda H et al. | Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8239580 |
| Kalach N et al. | Clarithromycin resistance and eradication of Helicobacter pylori in children. | 2001 | Antimicrob. Agents Chemother. | pmid:11408237 |
| Wakabayashi H et al. | Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia. | 2009 | Antimicrob. Agents Chemother. | pmid:19451301 |
| Mor N and Heifets L | Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8328792 |
| Rastogi N et al. | Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1667250 |
| Fernández-Roblas R et al. | In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. | 2000 | Antimicrob. Agents Chemother. | pmid:10602744 |
| Jung R et al. | Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes. | 2000 | Antimicrob. Agents Chemother. | pmid:10681358 |
| Conte JE et al. | Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. | 1996 | Antimicrob. Agents Chemother. | pmid:8807050 |
| Ferro BE et al. | Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. | 2016 | Antimicrob. Agents Chemother. | pmid:27458221 |
| Nash KA and Inderlied CB | Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. | 1996 | Antimicrob. Agents Chemother. | pmid:8807078 |
| Kamoda O et al. | In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection. | 2006 | Antimicrob. Agents Chemother. | pmid:16940102 |
| Dean NC et al. | Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care. | 2006 | Antimicrob. Agents Chemother. | pmid:16569825 |
| Cavalieri SJ et al. | Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. | 1995 | Antimicrob. Agents Chemother. | pmid:7492101 |
| Moon JE et al. | Efficacy of macrolides and telithromycin against leptospirosis in a hamster model. | 2006 | Antimicrob. Agents Chemother. | pmid:16723556 |
| Tamaoki J et al. | Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. | 1995 | Antimicrob. Agents Chemother. | pmid:7486901 |
| Beeton ML et al. | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. | 2009 | Antimicrob. Agents Chemother. | pmid:19273669 |
| Bolhuis MS et al. | Clarithromycin significantly increases linezolid serum concentrations. | 2010 | Antimicrob. Agents Chemother. | pmid:20837753 |
| Tsuda T et al. | Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes. | 2008 | Antimicrob. Agents Chemother. | pmid:18212111 |
| Nash KA et al. | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. | 2009 | Antimicrob. Agents Chemother. | pmid:19171799 |
| Gikas A et al. | In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9756789 |
| Debets-Ossenkopp YJ et al. | Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. | 1998 | Antimicrob. Agents Chemother. | pmid:9756790 |
| Lonks JR and Medeiros AA | High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I. | 1993 | Antimicrob. Agents Chemother. | pmid:8239578 |
| Hoppe JE and Bryskier A | In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). | 1998 | Antimicrob. Agents Chemother. | pmid:9559823 |
| Champney WS and Tober CL | Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells. | 1999 | Antimicrob. Agents Chemother. | pmid:10348746 |
| Dever LL et al. | Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. | 1993 | Antimicrob. Agents Chemother. | pmid:8215288 |
| Tsaganos T et al. | Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. | 2016 | Antimicrob. Agents Chemother. | pmid:27044546 |
| Kashuba AD and Amsden GW | Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9527816 |
| Clark CL et al. | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. | 2007 | Antimicrob. Agents Chemother. | pmid:17876003 |
| Amsden GW et al. | Oral cimetidine prolongs clarithromycin absorption. | 1998 | Antimicrob. Agents Chemother. | pmid:9660986 |
| Ohtani H et al. | Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. | 2000 | Antimicrob. Agents Chemother. | pmid:10991836 |
| Berg HF et al. | Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. | 2004 | Antimicrob. Agents Chemother. | pmid:15504839 |
| Kohno Y et al. | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. | 2007 | Antimicrob. Agents Chemother. | pmid:17709469 |
| Spangler SK et al. | Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8192445 |
| Bohnert JA et al. | Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay. | 2016 | Antimicrob. Agents Chemother. | pmid:26824939 |
| Rastogi N and Labrousse V | Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. | 1991 | Antimicrob. Agents Chemother. | pmid:1828135 |
| Hardy RD et al. | Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. | 2003 | Antimicrob. Agents Chemother. | pmid:12709330 |
| De R et al. | Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. | 2009 | Antimicrob. Agents Chemother. | pmid:19204190 |
| Tomioka H et al. | Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells. | 2002 | Antimicrob. Agents Chemother. | pmid:11796367 |
| Miltner EC and Bermudez LE | Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. | 2000 | Antimicrob. Agents Chemother. | pmid:10858369 |
| Perronne C et al. | Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1656860 |
| Fass RJ | Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. | 1993 | Antimicrob. Agents Chemother. | pmid:8257127 |
| Kawai Y et al. | Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. | 2013 | Antimicrob. Agents Chemother. | pmid:23459497 |
| Shinkai M et al. | Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression. | 2006 | Antimicrob. Agents Chemother. | pmid:16641444 |
| English ML et al. | Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. | 2012 | Antimicrob. Agents Chemother. | pmid:22290969 |
| Jorgensen JH et al. | Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. | 1991 | Antimicrob. Agents Chemother. | pmid:1834012 |
| Truffot-Pernot C et al. | Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. | 1991 | Antimicrob. Agents Chemother. | pmid:1834015 |
| Ji B et al. | Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. | 2008 | Antimicrob. Agents Chemother. | pmid:18391038 |
| Atkinson BA et al. | Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. | 1995 | Antimicrob. Agents Chemother. | pmid:8619588 |
| Fernandez-Martin J et al. | Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. | 1991 | Antimicrob. Agents Chemother. | pmid:1836943 |
| Konstantinidis T et al. | Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps. | 2016 | Antimicrob. Agents Chemother. | pmid:26643338 |
| Ferro BE et al. | Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. | 2016 | Antimicrob. Agents Chemother. | pmid:26643335 |
| Goldstein EJ et al. | Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. | 1998 | Antimicrob. Agents Chemother. | pmid:9593139 |
| van Doorn LJ et al. | Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. | 2001 | Antimicrob. Agents Chemother. | pmid:11302817 |
| Spangler SK et al. | Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. | 1998 | Antimicrob. Agents Chemother. | pmid:9593160 |
| Cheng KL et al. | Effect of grapefruit juice on clarithromycin pharmacokinetics. | 1998 | Antimicrob. Agents Chemother. | pmid:9559810 |
| Piccolomini R et al. | In vitro activity of clarithromycin against intracellular Helicobacter pylori. | 2001 | Antimicrob. Agents Chemother. | pmid:11302831 |
| Segreti J et al. | In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. | 1987 | Antimicrob. Agents Chemother. | pmid:2952061 |
| Alhajlan M et al. | Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. | 2013 | Antimicrob. Agents Chemother. | pmid:23545534 |
| Benson CA et al. | In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. | 1987 | Antimicrob. Agents Chemother. | pmid:2952063 |
| Carr RA et al. | Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. | 1998 | Antimicrob. Agents Chemother. | pmid:9593146 |
| Barry AL et al. | In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. | 1987 | Antimicrob. Agents Chemother. | pmid:2952064 |
| Sörberg M et al. | Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. | 1998 | Antimicrob. Agents Chemother. | pmid:9593154 |
| Burucoa C et al. | T2182C mutation is not associated with clarithromycin resistance in Helicobacter pylori. | 2005 | Antimicrob. Agents Chemother. | pmid:15673794 |
| Woosley LN et al. | CEM-101 activity against Gram-positive organisms. | 2010 | Antimicrob. Agents Chemother. | pmid:20176910 |
| Bermudez LE et al. | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. | 2007 | Antimicrob. Agents Chemother. | pmid:17296742 |
| Chin NX et al. | Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. | 1987 | Antimicrob. Agents Chemother. | pmid:2953303 |
| Bowie WR et al. | In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. | 1987 | Antimicrob. Agents Chemother. | pmid:2953304 |
| Derouin F et al. | Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis. | 1992 | Antimicrob. Agents Chemother. | pmid:1482160 |
| Floyd-Reising S et al. | In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. | 1987 | Antimicrob. Agents Chemother. | pmid:2955742 |
| Barry AL et al. | In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. | 1988 | Antimicrob. Agents Chemother. | pmid:2840016 |
| Lee JH et al. | Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. | 2005 | Antimicrob. Agents Chemother. | pmid:15793150 |
| Ji B et al. | Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. | 1996 | Antimicrob. Agents Chemother. | pmid:8834886 |
| Yamamoto T et al. | Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. | 1996 | Antimicrob. Agents Chemother. | pmid:8834892 |
| Fernandes PB et al. | Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. | 1987 | Antimicrob. Agents Chemother. | pmid:2957954 |
| Walker KJ et al. | Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model. | 1994 | Antimicrob. Agents Chemother. | pmid:7811010 |
| Bogdanovich T et al. | Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae. | 2006 | Antimicrob. Agents Chemother. | pmid:16495248 |
| Jones RN et al. | Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. | 2010 | Antimicrob. Agents Chemother. | pmid:20660671 |
| Koh WJ et al. | Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only. | 2013 | Antimicrob. Agents Chemother. | pmid:23183432 |
| Kosowska-Shick K et al. | Comparative antipneumococcal activities of sulopenem and other drugs. | 2009 | Antimicrob. Agents Chemother. | pmid:19307366 |
| Berti AD et al. | Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. | 2012 | Antimicrob. Agents Chemother. | pmid:22802248 |
| Meyer JM et al. | In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. | 1997 | Antimicrob. Agents Chemother. | pmid:9210696 |
| Zhanel GG and Karlowsky JA | In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae. | 2009 | Antimicrob. Agents Chemother. | pmid:19139284 |
| Garey KW et al. | Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. | 1999 | Antimicrob. Agents Chemother. | pmid:10223928 |
| Fontana C et al. | New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. | 2002 | Antimicrob. Agents Chemother. | pmid:12435674 |
| Noreddin AM et al. | Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. | 2002 | Antimicrob. Agents Chemother. | pmid:12435719 |
| Bergman KL et al. | Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. | 1999 | Antimicrob. Agents Chemother. | pmid:10223956 |